Aug 07, 2025 1:08pm EDT Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Aug 06, 2025 9:15am EDT Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Mar 31, 2025 3:45pm EDT Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Mar 18, 2025 8:45am EDT Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Mar 13, 2025 9:00am EDT Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
